Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases. The company is headquartered in San Clemente, California and currently employs 783 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing novel therapies for the treatment of glaucoma, corneal disorders, and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products, which includes insertion of a micro-scale device or drug delivery system designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and MIGS biosensors to measure pressure within the eye; bio-activated pharmaceuticals to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders; transdermal pharmaceuticals that are applied to the eyelid and designed to treat dry eye, presbyopia, glaucoma and other ocular surface diseases and disorders; and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.